Overview
- Tempus will pay $1.5 billion for Personalis, valuing the company at $16.25 a share and folding Personalis’s NeXT Personal minimal residual disease test into its product set.
- The deal is structured as an all‑stock transaction with Tempus able to pay up to half the price in cash and a maximum exchange ratio of 0.3356 Tempus shares per Personalis share.
- Personalis’s NeXT Personal test detects tiny fragments of tumor DNA in blood to spot cancer return after treatment and already has Medicare coverage for three cancer indications.
- The companies have worked together since late 2023 and Tempus had built an equity stake in Personalis before the sale, a sequence that led to board approvals and the planned integration.
- Beyond product gains, the acquisition sets a concrete market price for proprietary cancer genomic data and will prompt scrutiny over how Tempus merges datasets, protects patient privacy, and commercializes results.